Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page 3 I0 B, F o# p+ N- a
6 ]3 R( u$ `! ]" v+ ~& M8 H8 {7 V! s7 o9 h2 M( C" X
Sub-category:
* f- V: r6 q u' RMolecular Targets
) S: i* e" X; l# S# Z* D9 i6 A* o
( [# A* k/ |8 }1 X5 L
Category:. j1 W" v0 L& D& Y. m
Tumor Biology
( t4 _- t9 T$ a. j8 F
% A9 K0 C$ }5 n/ F
' Z1 ?( H% q, ^, L$ I# zMeeting:4 p+ e& z+ z# X% r% ~
2011 ASCO Annual Meeting Q! F; C) Q6 p, D5 c# A
4 H$ w, `% A0 ^) L8 y/ c9 N
' c D% M9 D+ |3 _( O) f* @0 jSession Type and Session Title:
4 U p9 x) ~$ D4 hPoster Discussion Session, Tumor Biology
% L) Q# I% z1 r3 _. h* C: c o# O
B; q8 S" Z/ H3 `6 o
4 n) z r! S4 I- r: W" V% A& MAbstract No: \, c/ u+ c& D1 z& C
10517 , M" M+ P, o) [; \: n
. z/ ^9 P, W" D3 @; i ]! q
' h- Q$ u9 N% I4 B) ` x+ n
Citation:
& l; T+ g: _# w/ `& a5 B- g2 xJ Clin Oncol 29: 2011 (suppl; abstr 10517)
9 _! f* C( e: w' W: N3 ]5 a7 S8 i2 s+ V E
+ @6 N2 W, w8 d7 i3 r
Author(s):
9 H N* e& E( ^/ [0 |8 @J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
) v+ m4 B# }3 n- M# z2 L5 w) f# `: T# z8 |
6 `3 l% q) \% H8 G: `; ^: x
0 |. l/ w4 y) a% yAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.4 M8 c& m/ z& v4 U3 p
! ?) S$ Q$ u; m
Abstract Disclosures
7 ]0 x1 O, C, {1 s- J7 ]6 z0 X; I
' g: G8 o% x' c7 b7 eAbstract:+ o% V {6 j' j s$ W8 x
- V' k6 ?( c' c' V2 @- ~# R" r% `7 O* X6 s! d
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
/ I/ O! q( f0 J
* R6 }1 w( p" R& I! g9 o, q: x
; i7 G$ r* C& P |
显身卡
